Literature DB >> 7660331

New and future antibiotics in the treatment of acute respiratory tract infections.

R Wise.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7660331      PMCID： PMC1021181          DOI： 10.1136/thx.50.3.223

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  15 in total

1.  Comparative pharmacokinetic disposition of fluoroquinolones in the lung.

Authors:  R Wise; D R Baldwin; J M Andrews; D Honeybourne
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

2.  In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.

Authors:  M A Cooper; J M Andrews; J P Ashby; R S Matthews; R Wise
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

3.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  Susceptibility of Streptococcus pneumoniae to penicillin: a prospective microbiological and clinical study.

Authors:  M E García-Leoni; E Cercenado; P Rodeño; J C Bernaldo de Quirós; D Martínez-Hernández; E Bouza
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

Review 5.  Randomized placebo-controlled trials of antibiotics for acute bronchitis: a critical review of the literature.

Authors:  P H Orr; K Scherer; A Macdonald; M E Moffatt
Journal:  J Fam Pract       Date:  1993-05       Impact factor: 0.493

6.  The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.

Authors:  R Wise; J M Andrews; N Brenwald
Journal:  J Antimicrob Chemother       Date:  1993-04       Impact factor: 5.790

7.  Bacteriology of hospital-acquired pneumonia.

Authors:  J G Bartlett; P O'Keefe; F P Tally; T J Louie; S L Gorbach
Journal:  Arch Intern Med       Date:  1986-05

8.  The levels of clarithromycin and its 14-hydroxy metabolite in the lung.

Authors:  D Honeybourne; F Kees; J M Andrews; D Baldwin; R Wise
Journal:  Eur Respir J       Date:  1994-07       Impact factor: 16.671

9.  In vitro activity of PD 127,391, an enhanced-spectrum quinolone.

Authors:  R Wise; J P Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

10.  Azithromycin concentrations at the sites of pulmonary infection.

Authors:  D R Baldwin; R Wise; J M Andrews; J P Ashby; D Honeybourne
Journal:  Eur Respir J       Date:  1990-09       Impact factor: 16.671
View more
  2 in total

Review 1.  The appropriate use of quinolones.

Authors:  A Percival
Journal:  Drugs       Date:  1996       Impact factor: 9.546

2.  Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections.

Authors:  J T MacFarlane; J Prewitt; P Gard; A Guion
Journal:  Br J Gen Pract       Date:  1996-06       Impact factor: 5.386
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.